跳至主要内容
临床试验/NCT00133731
NCT00133731已完成2 期

A Multinational, Randomized, Double-Blind, Double-Dummy, Exploratory, Parallel Group, Dose-Ranging Phase II Study to Evaluate Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Several Intravenous Regimens of Factor Xa Inhibitor Otamixaban (XRP0673), in Comparison to Intravenous Unfractionated Heparin, in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

Sanofi176 个研究点 分布在 4 个国家目标入组 947 人开始时间: 2004年9月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Sanofi
入组人数
947
试验地点
176
主要终点
Death, myocardial infarction, and urgent and non-urgent target vessel revascularization

研究概览

简要总结

The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older
  • Due to undergo non-urgent percutaneous coronary intervention (PCI)
  • Planned treatment with aspirin and clopidogrel

排除标准

  • Recent acute coronary syndrome
  • Patients at risk for, or with prior recent, bleeding
  • Patients have received recent prior treatment with an anticoagulant
  • Creatinine clearance > 30 ml/min

结局指标

主要结局

Death, myocardial infarction, and urgent and non-urgent target vessel revascularization

次要结局

  • Bleeding events

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (176)

Loading locations...

相似试验